56 results
Radiolabeled bevacizumab as a tracer of VEGF expression in patients with colorectal liver metastases
Evaluation of tumor localization of In-111 labeled bevacizumab and possible correlation with VEGF expression in patients with colorectal liver metastases.
The objective of this study is to evaluate the effect of different preventive strategies on the occurrence of macular edema after cataract surgery in non-diabetic and diabetic patients.
The primary objective is to determine the incidence of HFS in first line treatment with S-1 compared to capecitabine in patients with metastatic colorectal cancer. Secondary objectives include a comparison of efficacy.
The main aim of this study is to find out if the continuation of bevacizumab, in addition to standard 2nd & 3rd -line treatment, can help patients with NSCLC that has progressed to live longer. The study also aims to find out if continued…
Zie pagina 39-40 van het protocol MO22923 versie 2, 26 Mei 2011
Assessment whether the addition of bevacizumab to lomustine improves overall survival in patients with recurrent glioblastoma
To evaluate the efficacy, safety, tolerability, and pharmacokinetics of bevacizumab when added to postoperative radiotherapy with concomitant and adjuvant temozolomide (TMZ) and to determine whether the addition of anti-angiogenic therapy with…
Primary: Progression free survival.Secondary: Toxicity, overall survival, response rate, duration of response, translational research.
The objectives of this study are to assess the penetration of RO532441 into recurrent GBM by 89Zr-RO5323441 PET imaging and to quantify its uptake, to visualize and quantify 89Zr-RO5323441 organ distribution, and to measure effect of bevacizumab…
To determine long-term outcome of patients with advanced non-squamous NSCLC harbouring at diagnosis EGFR mutations with and without T790M mutation and treated with the combination of erlotinib and bevacizumab.
To estimate the treatment effect as measured by progression free survival(PFS) of subjects receiving AMG 386 (at 2 doses) in combination with paclitaxel + bevacizumabrelative to paclitaxel + bevacizumab + placebo.
In the present study we will perform a feasibility study to demonstrate that 89Zirconium-bevacizumab PET scanning can visualize multiple myeloma lesions. Data from the present study may be used to design further studies with regard to the expression…
To provide continued bevacizumab therapy as single agent or in combination with an anti-cancer drug to patients with cancer, who were previously enrolled in a F. Hoffmann-La Roche (Roche)/ Genentech sponsored bevacizumab study (i.e. the Parent, P-…
*To evaluate the safety and tolerability of RO7009789 and vanucizumab when administered in combination* To determine the maximum tolerated dose (MTD) (for the SC administration and potentially for the IV), route and recommended Phase II dose of…
This study will investigate whether treatment with Nivolumab is comparable to Bevacizumab in patients with Glioblastoma. We will measure this by comparing how many patients arestill alive after a certain period of time once they have started…
Phase A:Primary objective: Determining the feasibility of gemcitabine as a radiosensitizer in DIPG Secondary objective: Evaluation of efficacy in terms of clinical and radiological response rate and progression free survivalTertiary objectives:…
Primary:The primary objective of this study is to demonstrate that the overall progression-free survival (PFS) of 8 cycles of intermittent (2 times 4 cycles) chemotherapy (paclitaxel) is not inferior in efficacy, compared to 8 continuous cycles of…
Explore efficacy, safety, and feasibility (of an eventual future phase 3 trial) of intravenous immunoglobulins as treatment for patients with idiopathic inflammatory myopathies.
To explore if the addition of bevacizumab to temozolomide improves outcome as compared to treatment with temozolomide alone in patients with recurrent low grade and anaplastic glioma without combined 1p/19q co-deletion after prior radiotherapy and…
This study will evaluate 2 different treatment strategies : a combination of S 95005 and bevacizumab (experimental combination) and a combination of capecitabine and bevacizumab (control arm) as first-line treatment for metastatic colorectal cancer…